Partial

McEwen Copper: Los Azules Progress Report #4

Retrieved on: 
Thursday, August 4, 2022 - 12:00pm

TORONTO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- McEwen Copper Inc., a subsidiary of McEwen Mining Inc. (NYSE: MUX) (TSX: MUX), is pleased to report the latest assay results from its Los Azules project, which continues to deliver long intercepts of good grades.

Key Points: 
  • TORONTO, Aug. 04, 2022 (GLOBE NEWSWIRE) -- McEwen Copper Inc., a subsidiary of McEwen Mining Inc. (NYSE: MUX) (TSX: MUX), is pleased to report the latest assay results from its Los Azules project, which continues to deliver long intercepts of good grades.
  • Results from this drilling program will be used to update the 2017 Los Azules PEA (Preliminary Economic Assessment).
  • Partial results were reported in the Los Azules Progress Report #3 published on June 23, 2022.
  • As a matter of cross-referencing results presented in the Los Azules Progress Report #3 published on June 23, 2022, note that Section 36-36 was previously identified as Section A-A and Section 48-48 as Section C-C.

Pivot Point Consulting Issues “Q3 2022 Healthcare IT Trends Report” With 5 Key Insights and Implications for IT Leaders

Retrieved on: 
Thursday, August 4, 2022 - 12:00pm

Pivot Point Consulting, a Vaco Company, and 2022 #2 Best in KLAS: Overall IT Services Firm, today released its third quarter Healthcare IT Trends Report, focusing on five trends predicted to drive health IT decision-making in the second half of 2022.

Key Points: 
  • Pivot Point Consulting, a Vaco Company, and 2022 #2 Best in KLAS: Overall IT Services Firm, today released its third quarter Healthcare IT Trends Report, focusing on five trends predicted to drive health IT decision-making in the second half of 2022.
  • The report provides insights and recommendations to help leaders frame strategies, drive innovation and operate efficiently in an unpredictable, rapidly evolving environment.
  • As the cyber threat landscape evolves and infrastructures become more complex, so do the cybersecurity risks faced by healthcare.
  • A recent report from AT&T Cybersecurity found that healthcare organizations are focusing on a few key strategies to maintain their cybersecurity.

Showa Denko Announces 2022 2Q Consolidated Financial Results

Retrieved on: 
Thursday, August 4, 2022 - 6:00am

TOKYO, Aug 4, 2022 - (ACN Newswire) - Showa Denko K.K.

Key Points: 
  • TOKYO, Aug 4, 2022 - (ACN Newswire) - Showa Denko K.K.
  • (SDK; TSE:4004) today announced its 2022 2Q consolidated financial results.
  • 2022 Second Quarter Financial Results: Presentation Material
    Showa Denko Decides on Absorption-type Merger & Company Split, Trade Name Change, and Partial Amendment to Articles of Incorporation to Prepare for Its Transformation into Holding Company Structure
    Showa Denko K.K.
  • (SDK; TSE:4004, ADR:SHWDY) is a major manufacturer of chemical products serving from heavy industry to computers and electronics.

Frederick F. Buechel, Jr. M.D. Appointed Director of Robotic Assisted Knee Surgery at Lenox Hill Hospital in NYC

Retrieved on: 
Thursday, July 28, 2022 - 2:00pm

NEW YORK, July 28, 2022 /PRNewswire-PRWeb/ -- Lenox Hill Hospital, in the heart of New York City, is globally recognized for excellence in orthopedic care and has chosen Dr. Buechel as the new Director of Robotic Assisted Knee Surgery. Utilizing advanced robotic surgical technology provides Lenox Hill surgeons with unmatched precision that enables a minimally invasive approach for complex procedures with many benefits.

Key Points: 
  • NEW YORK, July 28, 2022 /PRNewswire-PRWeb/ -- Lenox Hill Hospital, in the heart of New York City, is globally recognized for excellence in orthopedic care and has chosen Dr. Buechel as the new Director of Robotic Assisted Knee Surgery.
  • Utilizing advanced robotic surgical technology provides Lenox Hill surgeons with unmatched precision that enables a minimally invasive approach for complex procedures with many benefits.
  • In his new role, Dr. Buechel's leadership will guide the robotic knee surgery program's growth and development to better serve the needs of patients.
  • He is the founder of the Robotic Joint Center in NYC and Taipei Postal Hospital in Taiwan.

Pivot Point Consulting Supports Live Deployment of OCHIN Epic Electronic Health Record System at Chicago's Erie Family Health

Retrieved on: 
Tuesday, July 19, 2022 - 4:18pm

NASHVILLE, Tenn., July 19, 2022 /PRNewswire/ -- Pivot Point Consulting, a Vaco Company, and recognized 2022 #2 Best in KLAS: Overall IT Services Firm, today announced the full deployment of OCHIN's Epic Electronic Health Record (EHR) system at Erie Family Health Centers (Erie), a nonprofit with 13 locations dedicated to the integrated healthcare needs of underserved communities across Chicago. This is the first instance of OCHIN Epic in Illinois.  

Key Points: 
  • Out of 45 community health centers in Illinois, Erie now ranks in the top 1% of community health centers nationally and #1 in Illinois for newborn delivery volume.
  • "We are thrilled to partner with Pivot Point and OCHIN to deploy the Epic platform across our community-based health centers," saidAmy Valukas, COO at Erie, who also served as a sponsor for the overall project.
  • The OCHIN Epic EHR technology enables all of Erie's community health centers to access, organize, store and share electronic medical records with four Epic hospital partners.
  • Pivot Point Consulting brings expert project management, resourcing and strategy services to their OCHIN partnership and this EHR transformation initiative.

Buenaventura Announces Second Quarter 2022 Production and Volume Sold per Metal Results

Retrieved on: 
Thursday, July 14, 2022 - 11:46pm

2022 outlook projections shown above are considered forward-looking statements and represent managements good faith estimates or expectations of future production results as of July 2022.

Key Points: 
  • 2022 outlook projections shown above are considered forward-looking statements and represent managements good faith estimates or expectations of future production results as of July 2022.
  • 2Q22 silver production was in line with expectations for the quarter.
  • 2Q22 gold production exceeded expectations due to an increase of treated ore and higher gold grades.
  • Production remained stable during the quarter with higher than expected gold production due to positive reconciliation of grades from the Mirador Norte open pit along with improved leaching permeability.

Runway Growth Finance Corp. Provides Second Quarter 2022 Portfolio Update

Retrieved on: 
Thursday, July 14, 2022 - 1:30pm

WOODSIDE, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Runway Growth Finance Corp. (Runway Growth) (Nasdaq: RWAY), a leading provider of flexible capital solutions to late- and growth-stage companies seeking an alternative to raising equity, today provided an operational and portfolio update for the second quarter ended June 30, 2022.

Key Points: 
  • WOODSIDE, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Runway Growth Finance Corp. (Runway Growth) (Nasdaq: RWAY), a leading provider of flexible capital solutions to late- and growth-stage companies seeking an alternative to raising equity, today provided an operational and portfolio update for the second quarter ended June 30, 2022.
  • Runway Growth delivered record second quarter originations, building momentum heading into the second half of the year, and further demonstrating the demand for our durable financing model, said David Spreng, Founder and CEO of Runway Growth.
  • Runway Growth has prudently added to our leverage levels and enters the second half of the year with the requisite capital to fund portfolio growth, execute against our long-term strategy, and drive shareholder value.
  • In the second quarter of 2022, Runway Growth funded nine investments: four investments in new portfolio companies, and five new investments in existing portfolio companies.

MicroEJ streamlines IoT software development with an embedded Virtual Execution Environment for Thales Cinterion® IoT Modules and Plug and Play IoT Devices

Retrieved on: 
Tuesday, July 5, 2022 - 2:00pm

As billions of devices are connected through 2G/3G/4G/5G and tomorrow 6G networks, Thales is teaming up with MicroEJ to introduce MICROEJ VEE universal software container for Thales Cinterion IoT Modules such as PLS83-W or EXS82-W and Cinterion IoT Plug and Play Devices such as EGX81 , along with its related software development tools and virtual modules.

Key Points: 
  • As billions of devices are connected through 2G/3G/4G/5G and tomorrow 6G networks, Thales is teaming up with MicroEJ to introduce MICROEJ VEE universal software container for Thales Cinterion IoT Modules such as PLS83-W or EXS82-W and Cinterion IoT Plug and Play Devices such as EGX81 , along with its related software development tools and virtual modules.
  • MICROEJ VEE secure container leverages both Thales Cinterion IoT connectivity solutions and Cinterion IoT Suite cloud platform and it enables:
    MicroEJ radically simplifies IoT software development by integrating simulation (development and testing on virtual devices), continuous integration and multi-object-oriented programming, where software components are integrated and tested separately.
  • Software applications are developed once and used on various Cinterion IoT Modules and IoT Plug and Play Devices without modification and software can be updated over-the-air for a large fleet of devices.
  • MICROEJ VEE enhances the digital IDs and security attributes embedded into the roots of Cinterion IoT Modules and IoT Plug and Play Devices.

Decibel Therapeutics Reports Positive Data from Interim Analysis of Ongoing Phase 1b Clinical Trial of DB-020 in Patients Receiving Cisplatin Chemotherapy

Retrieved on: 
Tuesday, June 28, 2022 - 12:00pm

BOSTON, June 28, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported positive top-line results from an interim analysis of its ongoing Phase 1b clinical trial of DB-020, a novel, proprietary formulation of sodium thiosulfate (STS) designed to protect against hearing loss in cancer patients receiving cisplatin chemotherapy. Cisplatin, one of the most commonly used chemotherapeutic agents, has severe dose-limiting side effects, including ototoxicity, which leads to permanent hearing loss in many patients. There are no approved therapies to prevent or treat cisplatin-induced ototoxicity.

Key Points: 
  • These data support the approach and rationale for DB-020 and represent an important step forward in the development of DB-020 for patients receiving cisplatin chemotherapy.
  • The interim analysis includes data collected as of February 4, 2022 from 19 cisplatin-nave cancer patients being treated with high doses of cisplatin every 21 or 28 days.
  • The Phase 1b clinical trial of DB-020 is an ongoing, randomized, double-blind, placebo-controlled, multicenter trial designed to determine safety and tolerability of transtympanic injections of DB-020 in cancer patients receiving high doses of cisplatin.
  • A randomized, double-blind, placebo-controlled, multicenter Phase 1b clinical trial of DB-020 in patients undergoing treatment with cisplatin is ongoing.

Notice regarding Issuance of Stock-Compensation-Type Stock Options (Stock Acquisition Rights)

Retrieved on: 
Tuesday, June 28, 2022 - 7:01am

Any acquisition of stock acquisition rights by transfer shall be subject to the approval by resolution of the Board of Directors of the Company.

Key Points: 
  • Any acquisition of stock acquisition rights by transfer shall be subject to the approval by resolution of the Board of Directors of the Company.
  • The Company shall deliver stock acquisition rights, the number of which shall equal the number of stock acquisition rights held by the holder of the Remaining Stock Acquisition Rights.
  • Accordingly, the issuance of the stock acquisition rights is not an issuance of shares with favorable terms.
  • Persons to be allotted stock acquisition rights, number of persons, and number of stock acquisition rights to be allotted